Cardiovascular Disease

Coronary heart disease prevalence in the US between 2011 and 2018 saw a statistically insignificant change, from 6.2% to 6.0%, respectively.

Available therapies combined with new approaches that address social determinants of health and other barriers to care can help, suggests new statement.

WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.

A Mayo Clinic study found certain cardiovascular conditions and risk factors are more strongly associated with cognitive decline in middle-aged women than men.

The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

In a new retrospective analysis, including smoking history in the 2013 ACC/AHA pooled cohort equations significantly improved ASCVD risk prediction.

New research presented at EuroEcho 2021 may help explain why some patients with long COVID-19 experience persistent dyspnea even 1 year after recovery.

AHA Scientific Sessions 2021 recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.